Book contents
Section 1 - Managing the basics
Published online by Cambridge University Press: 05 July 2015
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Androgens in Gynecological Practice , pp. 1 - 54Publisher: Cambridge University PressPrint publication year: 2015
References
1.Escobar-Morreale, HF, Carmina, E, Dewailly, D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012; 18: 146–70.Google Scholar
3.Azziz, R, Carmina, E, Dewailly, D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237–45.Google Scholar
4.Azziz, R, Carmina, E, Sawaya, ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347–62.Google Scholar
5.Escobar-Morreale, HF, Serrano Gotarredona, J, García Robles, R, et al. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist? Metabolism 1997; 46: 902–7.CrossRefGoogle ScholarPubMed
6.Rosner, W, Auchus, RJ, Azziz, R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405–13.CrossRefGoogle ScholarPubMed
7.Garn, SM. Types and distribution of the hair in man. Ann N Y Acad Sci 1951; 53: 498–507.CrossRefGoogle ScholarPubMed
8.Ferriman, D, Gallwey, JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–7.Google Scholar
10.Hatch, R, Rosenfield, RL, Kim, MH, Tredway, D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815–30.Google Scholar
11.Api, M, Badoglu, B, Akca, A, et al. Interobserver variability of modified Ferriman-Gallwey hirsutism score in a Turkish population. Arch Gynecol Obstet 2009; 279: 473–9.Google Scholar
12.Diamanti-Kandarakis, E, Kouli, CR, Bergiele, AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006–11.Google Scholar
13.Asuncion, M, Calvo, RM, San Millan, JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–8.Google ScholarPubMed
14.Zargar, AH, Wani, AI, Masoodi, SR, et al. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. Fertil Steril 2002; 77: 674–8.Google Scholar
15.Sagsoz, N, Kamaci, M, Orbak, Z. Body hair scores and total hair diameters in healthy women in the Kirikkale Region of Turkey. Yonsei Med J 2004; 45: 483–91.Google Scholar
16.Cheewadhanaraks, S, Peeyananjarassri, K, Choksuchat, C. Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thail 2004; 87: 459–63.Google Scholar
17.DeUgarte, CM, Woods, KS, Bartolucci, AA, Azziz, R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 2006; 91: 1345–50.CrossRefGoogle Scholar
18.Noorbala, MT, Kefaie, P. The prevalence of hirsutism in adolescent girls in Yazd, Central Iran. Iran Red Crescent Med J 2010; 12: 111–17.Google Scholar
19.March, WA, Moore, VM, Willson, KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544–51.CrossRefGoogle Scholar
20.Sanchón, R, Gambineri, A, Alpanes, M, et al. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 2012; 27: 1209–16.Google Scholar
21.Gabrielli, L, Aquino, EM. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod Biol Endocrinol 2012; 10: 96.Google Scholar
22.Knochenhauer, ES, Key, TJ, Kashar-Miller, M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–82.Google Scholar
23.Tellez, R, Frenkel, J. [Clinical evaluation of body hair in healthy women]. Rev Med Chil 1995; 123: 1349–54.Google ScholarPubMed
24.Zhao, JL, Chen, ZJ, Shi, YH, et al. [Investigation of body hair assessment of Chinese women in Shandong region and its preliminary application in polycystic ovary syndrome patients]. Zhonghua Fu Chan Ke Za Zhi 2007; 42: 590–4.Google Scholar
25.Moran, C, Tena, G, Moran, S, et al. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 2010; 69: 274–80.Google Scholar
26.Kim, JJ, Chae, SJ, Choi, YM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod 2011; 26: 214–20.Google Scholar
27.Azziz, R, Woods, KS, Reyna, R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745–9.Google Scholar
28.Glintborg, D, Henriksen, JE, Andersen, M, et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004; 82: 1570–9.Google Scholar
29.Unluhizarci, K, Gokce, C, Atmaca, H, et al. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue. Exp Clin Endocrinol Diabetes 2004; 112: 504–9.Google Scholar
30.Carmina, E, Rosato, F, Janni, A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2–6.CrossRefGoogle ScholarPubMed
31.Escobar-Morreale, HF, Sanchon, R, San Millan, JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93: 527–33.Google Scholar
32.Zawadzki, JK, Dunaif, A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif, A, Givens, JR, Haseltine, FP, Merriam, GR, editors. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 1992. pp. 377–84.Google Scholar
33.Martin, KA, Chang, RJ, Ehrmann, DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1105–20.CrossRefGoogle ScholarPubMed
34.Azziz, R, Waggoner, WT, Ochoa, T, et al. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998; 70: 274–8.Google Scholar
35.Alpanes, M, Gonzalez-Casbas, JM, Sanchez, J, et al. Management of postmenopausal virilization. J Clin Endocrinol Metab 2012; 97: 2584–8.CrossRefGoogle ScholarPubMed
36.Lord, JM, Flight, IH, Norman, RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003: CD003053.Google Scholar
37.Luque-Ramirez, M, Alvarez-Blasco, F, Botella-Carretero, JI, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2453–61.Google Scholar
38.Parkin, L, Sharples, K, Hernandez, RK, Jick, SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.Google Scholar
39.Breitkopf, DM, Rosen, MP, Young, SL, Nagamani, M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003; 67: 349–53.Google Scholar
40.Sanam, M, Ziba, O. Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better effect on acne, hirsutism and weight change? Saudi Med J 2011; 32: 23–6.Google Scholar
41.Luque-Ramirez, M, Mendieta-Azcona, C, Alvarez-Blasco, F, Escobar-Morreale, HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril 2009; 91: 2527–36.Google Scholar
42.Luque-Ramirez, M, Alvarez-Blasco, F, Escobar-Morreale, HF. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity 2009; 17: 3–9.CrossRefGoogle ScholarPubMed
43.Luque-Ramirez, M, Mendieta-Azcona, C, del Rey Sanchez, JM, et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009; 160: 469–80.Google Scholar
44.Luque-Ramirez, M, Escobar-Morreale, HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res 2010; 42: 815–20.Google Scholar
45.Moghetti, P, Tosi, F, Tosti, A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 89–94.Google Scholar
47.van Wayjen, RG, van den Ende, A. Clinical-pharmacological investigation of cyproterone acetate. Gynecol Invest 1971; 2: 282–9.Google Scholar
48.Wallace, C, Lalor, EA, Chik, CL. Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med 1993; 119: 1977.Google Scholar